Keros Therapeutics (KROS) Current Leases (2019 - 2026)

Keros Therapeutics (KROS) has reported Current Leases for 8 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 16.46% year-over-year to $2.6 million; the trailing twelve-month figure through Jun 2026 stood at $2.6 million (up 16.46% YoY), and the FY2025 full-year result was $2.4 million, up 21.74% from the prior year.
• Current Leases rose to $2.6 million in Q2 2026 per KROS's latest filing, from $2.4 million in the prior quarter.
• Across five years, Current Leases topped out at $2.6 million in Q2 2026 and bottomed at $455000.0 in Q3 2022.
• Historically, Current Leases has averaged $1.4 million across 5 years, with a median of $1.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Current Leases sank 47.22% in 2022, then jumped 203.93% in 2024.
• Over 5 years, Current Leases stood at $455000.0 in 2022, then soared by 120.88% to $1.0 million in 2023, then surged by 96.82% to $2.0 million in 2024, then climbed by 21.74% to $2.4 million in 2025, then gained by 7.85% to $2.6 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $2.6 million, $2.4 million, and $2.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.